Table 1.
Demographic characteristics of the included studies.
| First author | Country | Year | No. of patients | No. of lesions | Malignant | Borderline Tumors | Age (year, mean ± SD/median) | Tumor size (mm, mean ± SD/range) | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Basha et al. (20) | Egypt | 2021 | 609 | 647 | 178 | 32 | 48 ± 13.7 | NA | Pathological or 2-year follow-up |
| Chen et al. (21) | Taiwan | 2022 | 322 | 322 | 264 | 8 | 44 (20–83) | NA | Pathological |
| Guo et al. (22) | China | 2022 | 575 | 592 | 145 | 22 | 36.6 ± 13.9/46.5 ± 13.9a | NA | Pathological |
| Hiett et al. | USA | 2021 | 150 | 150 | 40 | 12 | 48.2 ± 1.7/47.5 ± 3.1a | 83.7 ± 5.2/101.4 ± 7.7a | Pathological |
| Lai et al. (24) | China | 2021 | 734 | 734 | 170 | 69 | 35 (29–46)/48 (36–55.3)a | NA | Pathological |
| Pelayo et al. (25) | Spain | 2023 | 122 | 122 | 41 | NA | 51.4 ± 15.7 | 94.2 ± 52.1 | Pathological |
| Poonyakanok et al. (26) | Thailand | 2023 | 357 | 357 | 61 | 11 | 43 (35–53) | 60 (42–83.8) 190 (159–277.5)a |
Pathological |
| Spagnol et al. (27) | Italy | 2023 | 514 | 514 | 89 | 25 | 51 (41–63) | NA | Pathological |
| Wang et al. (28) | China | 2023 | 445 | 445 | 180 | 31 | 40.19 ± 15.96/52.34 ± 13.15a | 95 ± 285/605 ± 492a | Pathological |
| Xie et al. (29) | China | 2022 | 453 | 453 | 269 | 48 | 48.8 ± 13.4 | 105.9 ± 64 | Pathological |
| Yang et al. (30) | China | 2023 | 1,179 | 1,179 | 213 | 67 | 38 (29–50) | 69 (51–94) | Pathological |
| Yoeli-Bik et al. (31) | USA | 2023 | 511 | 511 | 81 | 15 | 45.4 ± 14.8 | NA | Pathological (341) or 1-year follow-up |
NA, not available; SD, standard deviation.
a
Benign/malignant.